title: [Immunotherapy of cancer: promise and reality].
abstract: The notion that the immune system regulates cancer development is now well established. An overwhelming amount of data from animal models, together with compelling data from human patients, indicate that the immune system is instrumental in scanning and irradicating tumors. Analysis of individuals with congenital or acquired immunodeficiencies or patients undergoing immunosuppressive therapy has documented a highly elevated incidence of virally induced malignancies and cancers compared with immunocompetent individuals [1-3]. During the last decade, thanks to the breakthoughts in understanding the molecular mechanisms responsible for immune activation, the tumor antigen identification, the dendritic cell biology, the immunogenecity of tumors, the immune escape mechanisms, the host-tumor relationship, we are facing a new area of tumor immunotherapy. The basic advances were translated in therapeutical applications and have changed the view of immunotherapy from "a dream scenario" to a clinical fourth modality to cancer treatments. Multiple cancer trials using active immunization with vaccines or adoptive immunotherapy have been conducted with only very limited success. There are still a number of issues that still need to be resolved including a better understanding of immune escape mechanisms. Cancer vaccines continue to be evaluated and may lead to the emergence of clinically useful new treatments. A comprehensive approach to define the intricate molecular program initiated by tumor cells to resist to escape and the immune system of the host may help in breaking down the barriers to a more adapted cancer immunotherapy.
authors.affiliation: Laboratoire d'Immunologie des Tumeurs Humaines, Inserm U753, IFR-54, Institut Gustave-Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France. chouaib@igr.fr
authors.forename: Salem
authors.initials: S
authors.lastname: Chouaib
authors.forename: Faten
authors.initials: F
authors.lastname: El Hage
authors.forename: Houssem
authors.initials: H
authors.lastname: Benlalam
authors.forename: Fathia
authors.initials: F
authors.lastname: Mami-Chouaib
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy / Q000639:trends*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines